Follow
Koen Degeling, PhD, MSc
Koen Degeling, PhD, MSc
Scientific Director & Honorary Research Fellow
Verified email at unimelb.edu.au - Homepage
Title
Cited by
Cited by
Year
An inverse stage‐shift model to estimate the excess mortality and health economic impact of delayed access to cancer services due to the COVID‐19 pandemic
K Degeling, NN Baxter, J Emery, MA Jenkins, F Franchini, P Gibbs, ...
Asia‐Pacific Journal of Clinical Oncology 17 (4), 359-367, 2021
982021
Towards routine implementation of liquid biopsies in cancer management: it is always too early, until suddenly it is too late
MJ IJzerman, J de Boer, A Azad, K Degeling, J Geoghegan, C Hewitt, ...
Diagnostics 11 (1), 103, 2021
432021
A systematic review and checklist presenting the main challenges for health economic modeling in personalized medicine: towards implementing patient-level models
K Degeling, H Koffijberg, MJ IJzerman
Expert review of pharmacoeconomics & outcomes research 17 (1), 17-25, 2017
412017
Matching the model with the evidence: comparing discrete event simulation and state-transition modeling for time-to-event predictions in a cost-effectiveness analysis of …
K Degeling, MD Franken, AM May, MGH van Oijen, M Koopman, ...
Cancer epidemiology 57, 60-67, 2018
282018
Impact van de eerste COVID-19 golf op de reguliere zorg en gezondheid: Inventarisatie van de omvang van het probleem en eerste schatting van gezondheidseffecten
A Van Giessen, A De Wit, C Van den Brink, K Degeling, C Deuning, ...
Rijksinstituut voor Volksgezondheid en Milieu RIVM, 2020
252020
Accounting for parameter uncertainty in the definition of parametric distributions used to describe individual patient variation in health economic models
K Degeling, MJ IJzerman, M Koopman, H Koffijberg
BMC medical research methodology 17, 1-12, 2017
222017
Circulating tumour DNA as a potential cost-effective biomarker to reduce adjuvant chemotherapy overtreatment in stage II colorectal cancer
YH To, K Degeling, S Kosmider, R Wong, M Lee, C Dunn, G Gard, A Jalali, ...
Pharmacoeconomics 39 (8), 953-964, 2021
172021
A scoping review of metamodeling applications and opportunities for advanced health economic analyses
K Degeling, MJ IJzerman, H Koffijberg
Expert review of pharmacoeconomics & outcomes research 19 (2), 181-187, 2019
162019
Comparing strategies for modeling competing risks in discrete-event simulations: a simulation study and illustration in colorectal cancer
K Degeling, H Koffijberg, MD Franken, M Koopman, MJ IJzerman
Medical decision making 39 (1), 57-73, 2019
162019
Can we increase efficiency of CT lung cancer screening by combining with CVD and COPD screening? Results of an early economic evaluation
CM Behr, H Koffijberg, K Degeling, R Vliegenthart, MJ IJzerman
European radiology 32 (5), 3067-3075, 2022
142022
Comparison of timed automata with discrete event simulation for modeling of biomarker-based treatment decisions: an illustration for metastatic castration-resistant prostate cancer
K Degeling, S Schivo, N Mehra, H Koffijberg, R Langerak, JS de Bono, ...
Value in health 20 (10), 1411-1419, 2017
132017
Health economic models for metastatic colorectal cancer: a methodological review
K Degeling, M Vu, H Koffijberg, HL Wong, M Koopman, P Gibbs, ...
Pharmacoeconomics 38 (7), 683-713, 2020
112020
Introduction to metamodeling for reducing computational burden of advanced analyses with health economic models: a structured overview of metamodeling methods in a 6-step …
K Degeling, MJ IJzerman, MS Lavieri, M Strong, H Koffijberg
Medical Decision Making 40 (3), 348-363, 2020
92020
Evaluating the resource implications of different service delivery models for offering additional genomic findings
M Vu, K Degeling, M Martyn, E Lynch, B Chong, C Gaff, MJ IJzerman
Genetics in Medicine 23 (4), 606-613, 2021
72021
Lifetime health and economic outcomes of active surveillance, radical prostatectomy, and radiotherapy for favorable-risk localized prostate cancer
K Degeling, NM Corcoran, A Pereira-Salgado, AA Hamid, S Siva, ...
Value in Health 24 (12), 1737-1745, 2021
62021
Using metamodeling to identify the optimal strategy for colorectal cancer screening
H Koffijberg, K Degeling, MJ IJzerman, VMH Coupé, MJE Greuter
Value in health 24 (2), 206-215, 2021
52021
Evaluation of the performance of algorithms mapping EORTC QLQ-C30 onto the EQ-5D index in a metastatic colorectal cancer cost-effectiveness model
MD Franken, A de Hond, K Degeling, CJA Punt, M Koopman, ...
Health and Quality of Life Outcomes 18, 1-13, 2020
42020
Simulating progression-free and overall survival for first-line doublet chemotherapy with or without bevacizumab in metastatic colorectal cancer patients based on real-world …
K Degeling, HL Wong, H Koffijberg, A Jalali, J Shapiro, S Kosmider, ...
Pharmacoeconomics 38 (11), 1263-1275, 2020
42020
Health economic evidence for the use of molecular biomarker tests in hematological malignancies: A systematic review
M Vu, K Degeling, ER Thompson, P Blombery, D Westerman, ...
European Journal of Haematology 108 (6), 469-485, 2022
32022
Cell-free DNA at diagnosis for stage IV non-small cell lung cancer: Costs, time to diagnosis and clinical relevance
SN Koole, DCL Vessies, MMF Schuurbiers, A Kramer, RD Schouten, ...
Cancers 14 (7), 1783, 2022
32022
The system can't perform the operation now. Try again later.
Articles 1–20